Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
US Army
McKesson
Chinese Patent Office
Julphar
Accenture
Deloitte
QuintilesIMS
Baxter

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021726

« Back to Dashboard

NDA 021726 describes NIRAVAM, which is a drug marketed by Ucb Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the NIRAVAM profile page.

The generic ingredient in NIRAVAM is alprazolam. There are fifteen drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the alprazolam profile page.
Summary for 021726
Tradename:NIRAVAM
Applicant:Ucb Inc
Ingredient:alprazolam
Patents:2
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 021726

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Jan 19, 2005TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Apr 9, 2018Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:Apr 9, 2018Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Jan 19, 2005TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Apr 9, 2018Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 021726

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc NIRAVAM alprazolam TABLET, ORALLY DISINTEGRATING;ORAL 021726-002 Jan 19, 2005 ➤ Sign Up ➤ Sign Up
Ucb Inc NIRAVAM alprazolam TABLET, ORALLY DISINTEGRATING;ORAL 021726-001 Jan 19, 2005 ➤ Sign Up ➤ Sign Up
Ucb Inc NIRAVAM alprazolam TABLET, ORALLY DISINTEGRATING;ORAL 021726-002 Jan 19, 2005 ➤ Sign Up ➤ Sign Up
Ucb Inc NIRAVAM alprazolam TABLET, ORALLY DISINTEGRATING;ORAL 021726-003 Jan 19, 2005 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Johnson and Johnson
Medtronic
Daiichi Sankyo
Healthtrust
Deloitte
US Army
QuintilesIMS
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.